Showing results (361-370 of 3,787) with videos related to
Sort By:
Pageof 379
Oncoimmunology|February 1, 2020
Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphomaM Kazim Panjwani, Matthew J Atherton, Martha A MaloneyHuss, et al.Oncoimmunology|February 1, 2020
The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non-small-cell lung cancer: a real-life retrospective studyR Dupont, E Bérard, F Puisset, et al.Oncoimmunology|February 1, 2020
The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemiaZi-Jun Xu, Yu Gu, Cui-Zhu Wang, et al.Oncoimmunology|February 1, 2020
Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcomeShaokang Ma, Jonathan Chee, Vanessa S Fear, et al.Oncoimmunology|February 7, 2019
Safety and efficacy of Tet-regulated IL-12 expression in cancer-specific T cellsAhdab Alsaieedi, Angelika Holler, Pedro Velica, et al.Oncoimmunology|February 5, 2019
IL-33 increases ST2+ Tregs and promotes metastatic tumour growth in the lungs in an amphiregulin-dependent mannerE C Halvorsen, S E Franks, B J Wadsworth, et al.Oncoimmunology|February 5, 2019
Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cellsFiamma Salerno, Aurelie Guislain, Julian J Freen-Van Heeren, et al.Oncoimmunology|February 5, 2019
Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancerEmelie Rådestad, Charlotte Klynning, Arwen Stikvoort, et al.Oncoimmunology|February 5, 2019
PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factorZhi-Liang Wang, Guan-Zhang Li, Qiang-Wei Wang, et al.Oncoimmunology|December 5, 2018
Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinomaKenzo Ohara, Takayuki Ohkuri, Takumi Kumai, et al.Pageof 379